PLYMOUTH MEETING, Pa., Feb. 28, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:
Leerink Partners Global Biopharma Conference 2024
Barclays 26th Annual Global Healthcare Conference
A webcast of the fireside chats will be available on the investor page of Harmony's website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
This email address is being protected from spambots. You need JavaScript enabled to view it.
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$36.89 |
| Daily Change: | -1.08 -2.84 |
| Daily Volume: | 453,727 |
| Market Cap: | US$2.120B |
August 26, 2025 June 05, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
